A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

Imdelltra significantly improves survival in SCLC patients post-platinum chemotherapy, meeting primary endpoints in the DeLLphi-304 trial. As a BiTE immunotherapy, Imdelltra enhances T cell-cancer ...

The anti-cancer drug durvalumab used in immunotherapy delivers a 66-month survival breakthrough for lung cancer patients, ...

Clinical predictors of response to immunotherapy in patients with extensive-stage small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

Timing of consolidation durvalumab significantly impacts survival for patients with locally advanced non-small cell lung ...

The company said that responding patients lived longer overall, with a median survival of 16.2 months. ・The data come from ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...

Medicaid expansion under the ACA improved long-term survival for younger adults with operable lung cancer, despite no earlier ...